Introduction：Basic information about CAS 1093403-33-8|SRT 2104, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | SRT 2104 |
|---|
| CAS Number | 1093403-33-8 | Molecular Weight | 516.638 |
|---|
| Density | 1.5±0.1 g/cm3 | Boiling Point | / |
|---|
| Molecular Formula | C26H24N6O2S2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | 4-methyl-N-[2-[3-(morpholin-4-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]-2-pyridin-3-yl-1,3-thiazole-5-carboxamide$ |
|---|
| Synonym | More Synonyms |
|---|
SRT 2104 BiologicalActivity
| Description | SRT 2104 is a brain-permeable activator of SIRT1, used for the research of type 2 diabetes mellitus and Huntington's disease. |
|---|
| Related Catalog | Signaling Pathways >>Cell Cycle/DNA Damage >>SirtuinSignaling Pathways >>Epigenetics >>SirtuinResearch Areas >>Cancer |
|---|
| Target | SIRT1 |
|---|
| In Vitro | SRT 2104 (3 μM) reduces p65/RelA acetylation levels in C2C12 cells[1]. |
|---|
| In Vivo | SRT2104 (100 mg/kg, p.o.) improves whole-body physiology and extends lifespan in mice fed a standard diet. SRT2104 increases mitochondrial content and suppresses the inflammatory response in SD-fed mice. SRT2104 also changes the gene expression profile differently in liver and muscle. Short-term SRT2104 preserves muscle and bone mass[1]. 0.5% SRT2104 diet penetrates the blood-brain barrier, attenuates brain atrophy, improves motor function, and extends survival in a mouse model of Huntington's disease[2]. |
|---|
| Cell Assay | C2C12 cell line is cultured in low glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin. Cells are treated with vehicle (0.1% DMSO) or 3 μm SRT2104 for 24 h and then harvested for protein and Western blotting[1]. |
|---|
| Animal Admin | For the longevity study, diets are started at 28 weeks of age after randomization into two groups of 100 mice per group. Mice are fed a standard AIN-93G diet (SD; carbohydrate:protein:fat ratio of 64:19:17 percent of kcal), or a SD supplemented with SRT2104. SRT2104 is added at a dose of 1.33 g drug per kg of chow, formulated to provide daily doses of 100 mg drug/kg bodyweight. For the hindlimb suspension study, starting at 4 months of age, C57BL/6 mice are fed either a standard AIN-93G diet (SD; carbohydrate:protein:fat ratio of 64:19:17 percent of kcal) or a SD supplemented with SRT2104 for 4 weeks prior to suspension, and then for an additional 2 weeks during the suspension. Diets are formulated so mice receive a daily dose of 200 mg drug/kg of bodyweight. For the 48-h fasting study, mice are fed either SD or a SD supplemented with SRT2104 (100 mg/kg) for 6 weeks prior to sacrifice. This is the same diet as for the longevity study mice. For the whole-body SIRT1 knockout and muscle-specific SIRT1 knockout mouse models, mice are maintained on house chow (carbohydrate:protein:fat ratio of 58:24:18 percent of kcal) for the course of their lives[1]. |
|---|
| References | [1]. Mercken EM, et al. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell. 2014 Oct;13(5):787-96. [2]. Jiang M, et al. Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52. |
|---|
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|
| Molecular Formula | C26H24N6O2S2 |
|---|
| Molecular Weight | 516.638 |
|---|
| Exact Mass | 516.140198 |
|---|
| PSA | 144.62000 |
|---|
| LogP | 4.10 |
|---|
| Index of Refraction | 1.761 |
|---|
| InChIKey | LAMQVIQMVKWXOC-UHFFFAOYSA-N |
|---|
| SMILES | Cc1nc(-c2cccnc2)sc1C(=O)Nc1ccccc1-c1cn2c(CN3CCOCC3)csc2n1 |
|---|
| Storage condition | -20℃ |
|---|
Synonyms
| 4-methyl-N-(2-(3-(morpholinomethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)-2-(pyridin-3-yl)thiazole-5-carboxamide |
| CS-0955 |
| 5-Thiazolecarboxamide, 4-methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl)- |
| 5-Thiazolecarboxamide,4-methyl-N-[2-[3-(4-morpholinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-(3-pyridinyl) |
| 4-Methyl-N-{2-[3-(4-morpholinylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl}-2-(3-pyridinyl)-1,3-thiazole-5-carboxamide |
| sirtuin modulator |
| SRT 2104 |
| GSK2245840 |
| SRT-2104 |
